deepull appoints Didier Deltort to its Board of Directors
May 22 2024 - 3:00AM
deepull appoints Didier Deltort to its
Board of Directors
Barcelona, Spain – 22 May 2024
– deepull, a medical diagnostics company developing
culture-free diagnostic solutions for rapid pathogen identification
for sepsis and other acute infections, today announces the
appointment of Didier Deltort to its Board of Directors.
Didier Deltort is a Senior Advisor
at Mérieux Equity Partners. Didier has spent over 30 years
leading healthcare technology innovation and businesses around the
world. His previous experience includes senior leadership positions
at GE Healthcare, Boston Scientific, Zimmer Biomet and HP
Inc. He will be the representative of the Pertinence Invest 2
Fund managed by UI Investissement and advised by Mérieux Equity
Partners.
During his 14-year tenure at GE Healthcare,
Didier held senior roles across Europe, the Middle East and the
United States, including SVP of Global Monitoring Solutions and
Managing Director of GE Healthcare Finland. Whilst at GE
Healthcare, he worked across a range of diagnostic imaging product
segments, as well as leading the development of various
patient monitoring devices for acute care settings. As EMEA
President at Zimmer Biomet, a leader in musculoskeletal
healthcare, he led the marketing, sales and distribution of its
entire product range, including surgical robotics solutions. Prior
to Zimmer Biomet, Didier was Senior Vice President and General
Manager, Global Healthcare Solutions and Partnerships at Boston
Scientific. Most recently, he was Global President for HP Inc.’s
Personalization & 3D Printing division, based in Barcelona.
Didier received his Master’s in Biomedical
Engineering from the Université de Technologie de
Compiègne, France.
Rick Ivey, Chairman of the Board of
Directors at deepull, commented: “Didier’s extensive
medical device and technology experience will be invaluable to
deepull as it progresses its clinical trials for UllCORE, its
innovative sepsis diagnostics product, and ultimately heads towards
commercialization. We look forward to welcoming Didier to the Board
and benefitting from his insights and contributions.”
Didier Deltort, newly appointed Board
Member of deepull, added: “After many years working
on innovative healthcare technologies, it’s clear to me that
deepull’s diagnostic approach could transform laboratory PCR
testing for sepsis patients, as well as a range of other acute
infections. I look forward to working closely with the Management
and the Board as deepull heads towards important clinical and
commercial milestones.”
-Ends-
Notes to editors
About deepull
deepull is a medical diagnostics company
developing culture-free diagnostic solutions for sepsis and acute
infections. Founded in 2020 in Barcelona by the founders of STAT-Dx
(sold to QIAGEN in 2018), deepull has assembled a team of
world-class experts to create rapid and accessible diagnostic
solutions. Visit www.deepull.com for more and follow us on
LinkedIn.
deepull is developing a 1 hour,
direct-from-blood PCR test targeting 95% of sepsis-causing
pathogens. The test will extract total microbial DNA from 8 mL of
whole blood and include 50 reportable results. The test runs on the
deepull UllCORE instrument; a benchtop system with sample-to-result
automation being designed to meet the needs of any hospital
clinical laboratory.
For more information, please contact:
deepull
Agustina
Boullaude Email:
aboullaude@deepull.com
ICR Consilium
Amber Fennell / Lucy Featherstone
Email: deepull@consilium-comms.com